Fulcrum Therapeutics Income Statement (2019-2026) | FULC

Income Statement Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
4.38M4.93M5.06M2.59M1.88M1.18M0.69M0.29M0.88M0.76M0.87M80.00M
Operating items
Research & Development (Quarter)
17.38M17.08M18.91M17.83M25.02M15.37M18.57M16.71M17.85M18.24M19.00M19.77M17.26M14.64M11.71M13.40M12.99M14.30M15.42M14.08M
Selling, General & Administrative (Quarter)
6.68M8.63M9.71M10.76M11.10M9.71M10.13M11.52M10.32M9.96M9.86M10.06M10.25M8.42M7.72M7.00M6.83M7.56M7.28M8.10M
Restructuring Costs (Quarter)
0.47M-0.04M2.06M
Operating Expenses (Quarter)
24.06M25.70M28.62M28.59M36.12M25.54M28.66M28.23M28.17M28.20M28.86M29.83M27.51M25.13M19.43M20.40M19.82M21.86M22.69M22.19M
Operating Income (Quarter)
-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-20.40M-19.82M-21.86M-22.69M-22.19M
EBIT (Quarter)
-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-20.40M-19.82M-21.86M-22.69M-22.19M
Non-operating items
Interest & Investment Income (Quarter)
0.03M0.05M0.07M0.07M0.17M0.62M1.84M3.16M3.51M3.42M3.24M2.96M2.92M3.43M2.86M2.75M2.52M2.26M2.36M3.29M
Other Non Operating Income (Quarter)
Net income details
EBT (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Profit After Tax (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Income from Continuing Operations (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Consolidated Net Income (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Income towards Parent Company (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-17.30M-19.59M-20.33M-18.89M
Additional items
EPS (Basic) (Quarter)
-0.60-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.89-0.35-0.27-0.28-0.28-0.31-0.31-0.25
EPS (Weighted Average and Diluted) (Quarter)
-0.60-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.87-0.35-0.27-0.28-0.28-0.31-0.31-0.25
Shares Outstanding (Weighted Average) (Quarter)
0.03M0.03M0.04M0.04M0.04M0.04M0.04M0.06M61.79M61.82M0.06M61.98M62.09M62.20M0.06M62.48M62.54M62.54M0.06M76.22M
Shares Outstanding (Diluted Average) (Quarter)
0.03M0.04M0.04M0.04M0.04M0.05M0.04M0.06M61.79M61.82M0.06M61.98M63.68M62.41M0.06M62.48M62.54M62.54M0.06M76.22M
EBITDA (Quarter)
-19.65M-20.79M-23.79M-26.62M-34.05M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-27.17M52.49M-20.95M-16.82M-17.71M-19.82M-19.44M-20.40M-19.58M
Shares Outstanding (Quarter)
21.0040.53M40.63M40.68M41.01M52.05M52.10M61.76M61.82M61.82M61.92M62.14M62.25M53.94M53.97M53.98M54.09M54.11M66.58M66.61M